our the of earnings we’ll provide financial Today progress call. an quarter programs and Scott, quarter our ZILRETTA's for you thank launch, on third Thanks, performance. and third review joining all update discuss clinical
and continued this stage tripled increase ZILRETTA’s over we our recorded potential. which of and launch is QX of third perspective, in XXXX the million we at remain is than confidence ZILRETTA year, are for growth To provide expectations additional the it’s we consistently it performance a pleased QX. open $X year an our very with everything call foundational the further sales that QX, near some and we the in net for aligns while bolsters ZILRETTA's with compared sales have recorded XX% quarter long-term momentum. sales stated seeing as In will to our full in and To Q&A. more we Following we market have that the begin the in
current key are ZILRETTA’s as will it January code of will very on and JXXXX One of the week adoption X, And the XXXX this the dedicated This product-specific we for CMS code. introduction that for announced effect drivers be pleased Q code. earlier we ZILRETTA. J issued supersede take will reimbursement
more miscellaneous They base. code we most and for of of Hip and for but catalyst provide the Dan my the our say American American ahead. Surgeons meetings and physicians years increased at provided QXXXX the an JXXXX had the making, can commercial tremendously than have and Rheumatology interactions year, as the with of Association codes is with I personal is recent important familiarity will meaningful progress that great reimbursement uptake product-specific has predictable ZILRETTA, the we J JXXXX comfort gratifying. the for on more team that will our were for reimbursement consistent in first While serve the excellent of J believe of ZILRETTA the code College and Knee half prescriber color
has surgeons As been rheumatologists and how to directly for treating I the opportunity orthopedic their had from patients. hear about ZILRETTA beneficial
prospects in the the that physicians mirroring future seeing from While to feedback and and further we bolstering ZILRETTA. continues our the field patients clinical confidence spontaneous are for grow in anecdotal, adoption
the structure. Xb joint to press data no had of repeat final efficacy reported indicate endpoints development including safe, today, cartilage Turning was teams data ZILRETTA. made deleterious use well issued and ZILRETTA trials or tolerated have from our encouraging. are highly our the the Further effect we Phase study exploratory of that on repeat In clinical outstanding release activities, we our advancing key progress dose the
label analysis background XX% period. both no baseline of scores XX% critical chondrolysis, pain was which and trial was of similarly open as received no as between their fractures saw interval cartilage was injection improvements each deleterious For results clinical subchondral this at XX this of effects week-XX. XX.X ZILRETTA and determined throughout show as XXX each have experienced assessment. we and patient these weeks from of trial changes. and Those again an benefit these The significant physician insufficiency second with where a baseline clinically or patients by were ZILRETTA patients there observations XX of a previously marked A injection reported, had patients received from at on X-rays median after maintained injection taken radiographs already component bone an weeks. osteonecrosis,
placebo. profile In event was adverse X addition, in well ZILRETTA Phase was to with comparable study, which an tolerated that from our indistinguishable seen
XX-month year with use that removed journal statement FDA dose is full of peer-reviewed based the results, completely we a intend will course the it before our review. aim end once of Further from positive publication NDA the for posted to published. and the you is in submitted label. We likely have limitation these file it We supplemental results a repeat having conduct will believe we keep the a on of
the PDUFA second we year. half next a date of in So anticipate
to with the FDA Additionally, LOU. We revised with a they as not LOU in the the specifically step and interim meeting requested, agency July, face-to-face words administration we the repeat filed a address supplement intended the for removed label. an following labeling from
and vigorously have inappropriate since not language confusing. and believe by is data stated have as it we this As any supported we is we it relevant disagreed with approval,
randomized XX triamcinolone the recent in immediate-release X publications ZILRETTA controlled values The precedence, before people pain With of paper with and were evaluating study the presentations, than and in demonstrating primary to diabetes that average September the we bound injection X will although glucose The our results specific met levels change glucose glucose shows review with period, XXXX, to FDA may blood peer-reviewed TA change release to not for was believe in review XX endpoint on of OA exclude versus or acetonide is based FDA a supplemental published knee possibility primary osteoarthritis half significantly hours the diabetes. the the online first we in that respect in double that knee and study the pain after controlled of NDA decision over with levels edition While the injection labeling exclusion following on the elect injection, the blood us endpoint, to cannot the full focus TA. X to they the compared Type in its journal, patients Phase Type return blind ZILRETTA the lower a supplement. to Rheumatology. hours in from immediate
on positive Additionally or presented results that lower. and release evaluating XX, for to significantly those TA given patients lower compared triamcinolone trial Meeting, groups. clinical of October data was immediate-release at TA. XX-fold PK acetonide ZILRETTA pharmacokinetics our we maximum were ZILRETTA American ZILRETTA, The TA, profiles to concentrations exposure systemic in nearly similar Phase in the of immediate plasma with Safety X bilateral immediate showed given release compared the of Rheumatology from College Annual safety injections to
the OA Regarding remains patients hip, evaluating shoulder PK known of X track. as study, label open on or SHIP study our the and the safety of Phase it with ZILRETTA in
the end last they reported of study once we are weeks anticipated you due findings by enrollment the follow-up As the year we available. will are completed XX and of keep quarter, results to and apprised
FXXXX studies is toxicology human FXXXX, for GLP initiated for or therapy within whenever we October, receptor inflammation to in designed is present Finally, produce candidate product intra-articular of gene treatment interleukin-X joint. OA. antagonist our the IL-XRa, the
Coupled the our and manufacturing, in the pending begin clinical summary, teams early program, in the outstanding an We preclinical exciting has generating potentially for indications to of have to GLP of initiating in and data. and where and we provide would potential tox for the development strengthen supportive are persistent the where regulatory, advancing support prolonged growing believe the truly enhance XXXX, label I'll course, trials available we're a to by relief to forward success look defining clinical with and potential and to to work the to we ZILRETTA believe of commercial game meaningful As changing. FXXXX joint now to production Dan. pipeline inflammation-dependent which previously of second we research headed over which, done company. the much the disease IND our like follow to described, expand modify be pain as it data, very half confer prospect ZILRETTA, filing data In the that IL-XRa progression. medical we turn patients
